Plandai Biotechnology, Inc. announced a license agreement with Coyne Healthcare for a new product which will utilize the company's Pheroid(r) entrapped Phytofare(r) catechin complex -- trade named ‘ph(TM)'-- in a high-end consumer product for therapeutic and various other applications. Under the agreement, Plandai will prepare the ph2 capsules for Coyne who will then bottle, package and sell the product, first in South Africa with an international launch targeted later this year. ph2(TM) is the combination of the nano-entrapment system, Pheroid(r) with the Company's Phytofare(r) catechin complex.

Pheroid(r) encapsulates, or entraps, the Phytofare(r) in a long-chain fatty-acid which both improves absorption and protects the Phytofare(r) against metabolization during the digestive process. Pheroid(r) is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream. The new Coyne Healthcare product represents the first application of Phytofare(r) and Pheroid(r) (branded ‘ph(TM)') in a commercial product intended for human use.